Edurne López Soberón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edurne López Soberón has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Suárez
Department of Cardiology, Hospital Central Defense Gomez Ulla, 28047 Madrid, Spain
1 shared publication - Beatriz Tendero de la Asunción
General Biochemistry Section, Department of Clinical Analysis, Central Defense Hospital Gómez Ulla, Madrid, Spain, Spain
1 shared publication - Carlos Narváez-Mejía
Department of Nephrology, Hospital Universitario Puerta del Mar, 11009 Cádiz, Spain
1 shared publication - Carmen Ramos Alejos-Pita
Department of Cardiology, Central Defense Hospital Gómez Ulla, Madrid, Spain;Universidad de Alcalá, Spain
1 shared publication - Daniel Villa
Department of Nephrology, Clínica Universidad de Navarra, 31008 Navarra, Spain
1 shared publication - David Martí
Interventional Cardiology Unit, Department of Cardiology, Central Defense Hospital, University of Alcalá, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 13 November 2025
- Published by MDPI AG in Preprints.org
The Impact of Lipoprotein(a) Determination in Cardiovascular Risk Stratification Among People Living with HIV
Introduction: Human immunodeficiency virus (HIV) infection has become a chronic condition due to antiretroviral therapy (ART), which has increased life expectancy but is also associated with a higher burden of cardiovascular disease (CVD) in people living with HIV (PLHIV). Lipoprotein(a) [Lp(a)] is an independent cardiovascular risk biomarker; however, its role in PLHIV remains unclear. This study evaluated the relationship between Lp(a) and cardiovascular risk and explored its association with subclinical coronary artery disease. Materials and Methods: Cross-sectional study included PLHIV aged ≥40 years on stable ART with sustained viral suppression. Individuals with prior cardiovascular events or type 1/advanced type 2 diabetes were excluded. Lp(a) levels and clinical data were collected. Cardiovascular risk was estimated using validated clinical scores; participants with ≥10% risk underwent coronary computed tomography angiography (CTA) to assess coronary anatomy. Results: A total of 69 patients were included (81% male; mean age 54 years). The mean Lp(a) level was 66.7 nmol/L; 29% had ≥75 nmol/L and 23% ≥125 nmol/L. A non-significant inverse correlation was observed between Lp(a) levels and ART duration (r = –0.209; p = 0.08). Among those with elevated Lp(a), a higher proportion had vulnerable plaques on CTA, although this was not statistically significant. Conclusions: In this cohort of virologically suppressed PLHIV, an inverse trend was observed between ART duration and Lp(a) levels. In the subgroup of moderate-to-high cardiovascular risk, the prevalence of coronary plaque vulnerability features was higher among those with elevated Lp(a), highlighting a possible link between Lp(a) and subclinical atherosclerosis in this population.
- 13 November 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Impact of Lipoprotein(a) Determination in Cardiovascular Risk Stratification Among People Living with HIV
Introduction: Human immunodeficiency virus (HIV) infection has become a chronic condition due to antiretroviral therapy (ART), which has increased life expectancy but is also associated with a higher burden of cardiovascular disease (CVD) in people living with HIV (PLHIV). Lipoprotein(a) [Lp(a)] is an independent cardiovascular risk biomarker; however, its role in PLHIV remains unclear. This study evaluated the relationship between Lp(a) and cardiovascular risk and explored its association with subclinical coronary artery disease. Materials and Methods: Cross-sectional study included PLHIV aged ≥40 years on stable ART with sustained viral suppression. Individuals with prior cardiovascular events or type 1/advanced type 2 diabetes were excluded. Lp(a) levels and clinical data were collected. Cardiovascular risk was estimated using validated clinical scores; participants with ≥10% risk underwent coronary computed tomography angiography (CTA) to assess coronary anatomy. Results: A total of 69 patients were included (81% male; mean age 54 years). The mean Lp(a) level was 66.7 nmol/L; 29% had ≥75 nmol/L and 23% ≥125 nmol/L. A non-significant inverse correlation was observed between Lp(a) levels and ART duration (r = –0.209; p = 0.08). Among those with elevated Lp(a), a higher proportion had vulnerable plaques on CTA, although this was not statistically significant. Conclusions: In this cohort of virologically suppressed PLHIV, an inverse trend was observed between ART duration and Lp(a) levels. In the subgroup of moderate-to-high cardiovascular risk, the prevalence of coronary plaque vulnerability features was higher among those with elevated Lp(a), highlighting a possible link between Lp(a) and subclinical atherosclerosis in this population.
- Open Access
Percutaneous Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation and End-Stage Renal Disease on Hemodialysis: A Case Series
Non-valvular atrial fibrillation (NVAF) is the most common cardiac arrhythmia in the general population, and its prevalence increases among patients with chronic kidney disease (CKD) undergoing hemodialysis. This population presents high risk of both hemorrhagic and thrombotic events, with little evidence regarding the use of oral anticoagulation treatment (OAT) and multiple complications arising from it; however, stroke prevention with percutaneous left atrial appendage closure (LAAC) is an alternative to be considered. We retrospectively describe the safety and efficacy of percutaneous LAAC in eight patients with NVAF and CKD on hemodialysis during a 12-month follow-up. The mean age was 78.8 years (range 64–86; SD ± 6.7), and seven patients were male. The mean CHA2DS2-VASC and HAS-BLED scores were high, 4.8 (SD ± 1.5) and 3.8 (SD ± 1.3), respectively. Seventy-five percent of the patients were referred for this intervention due to a history of major bleeding, with gastrointestinal bleeding being the most common type, while the remaining twenty-five percent of the patients were referred because of a high risk of bleeding. The percutaneous LAAC procedure was successfully completed in 100% of the patients, with complete exclusion of the appendage without complications or leaks exceeding 5 mm. There was one death not related to the procedure four days after the intervention. Among the other seven patients, no deaths, cardioembolic events or major bleeding were reported during the follow-up period. In our sample, percutaneous LAAC appears to be a safe and effective alternative to anticoagulation in patients with NVAF and CKD on hemodialysis.
Open AccessPercutaneous Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation and End-Stage Renal Disease on Hemodialysis: A Case Series
Non-valvular atrial fibrillation (NVAF) is the most common cardiac arrhythmia in the general population, and its prevalence increases among patients with chronic kidney disease (CKD) undergoing hemodialysis. This population presents high risk of both hemorrhagic and thrombotic events, with little evidence regarding the use of oral anticoagulation treatment (OAT) and multiple complications arising from it; however, stroke prevention with percutaneous left atrial appendage closure (LAAC) is an alternative to be considered. We retrospectively describe the safety and efficacy of percutaneous LAAC in eight patients with NVAF and CKD on hemodialysis during a 12-month follow-up. The mean age was 78.8 years (range 64–86; SD ± 6.7), and seven patients were male. The mean CHA2DS2-VASC and HAS-BLED scores were high, 4.8 (SD ± 1.5) and 3.8 (SD ± 1.3), respectively. Seventy-five percent of the patients were referred for this intervention due to a history of major bleeding, with gastrointestinal bleeding being the most common type, while the remaining twenty-five percent of the patients were referred because of a high risk of bleeding. The percutaneous LAAC procedure was successfully completed in 100% of the patients, with complete exclusion of the appendage without complications or leaks exceeding 5 mm. There was one death not related to the procedure four days after the intervention. Among the other seven patients, no deaths, cardioembolic events or major bleeding were reported during the follow-up period. In our sample, percutaneous LAAC appears to be a safe and effective alternative to anticoagulation in patients with NVAF and CKD on hemodialysis.
- Open Access
- 1 December 2015
- Published by SciELO Espana/Repisalud in Sanidad Militar
- Vol. 71 (4) , 249-251
Paniculitis septal y sindrome de Löfgren en varon de 39 años
- 1 December 2015
- Published by SciELO Espana/Repisalud in Sanidad Militar
- Vol. 71 (4) , 249-251
Open AccessPaniculitis septal y sindrome de Löfgren en varon de 39 años